业绩总结 - 2021年第二季度总收入为4.35亿美元，同比增长62%（2020年为2.69亿美元）[7] - 筛查收入为2.64亿美元，同比增长101%（2020年为1.31亿美元），其中包括一项与Cologuard测试相关的1210万美元的一次性下调[7] - 精准肿瘤学收入为1.38亿美元，同比增长34%（2020年为1.03亿美元）[7] - 毛利率为69%，较2020年的63%有所提升，非GAAP毛利率为74%[7] - 调整后的EBITDA为-2700万美元，较2020年的-500万美元有所恶化[7] - 2021年第二季度末现金余额为13.08亿美元，较2020年末的12.23亿美元有所增加[7] 未来展望 - 2021年第三季度收入预期为4.20亿至4.35亿美元[8] - 全年收入预期为17.05亿至17.45亿美元[8] - 2021年销售与市场营销费用预期为6亿至6.25亿美元[12] - 研发费用预期为4.1亿至4.35亿美元[12] - 预计2022年将有超过100万人符合重新筛查资格[15] 用户数据 - 自Cologuard获批以来，已检测出超过20万个估计的前癌症病例[15]

Exact Sciences Corporation (NASDAQ:EXAS) Q1 2021 Earnings Conference Call May 4, 2021 5:00 PM ET Company Participants Erik Holznecht - IR Kevin Conroy - Chairman and CEO Jeff Elliott - CFO Conference Call Participants Brian Weinstein - William Blair Derik de Bruin - Bank of America Doug Schenkel - Cowen Brandon Couillard - Jefferies Daniel Arias - Stifel Catherine Schulte - Baird Daniel Brennan - UBS Vijay Kumar - Evercore ISI Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - SVB Leerink ...

Exact Sciences Corporation (NASDAQ:EXAS) Q4 2020 Earnings Conference Call February 16, 2021 5:00 PM ET Company Participants Erik Holznecht - Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Jeff Elliott - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Dan Arias - Stifel Derik de Bruin - Bank of America Doug Schenkel - Cowen Catherine Schulte - Baird Brian Weinstein - William Blair Patrick Donnelly - Citi Dan Brennan - UBS Puneet Souda - SVB Leerink Sand ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 _____________________________________________________________________________ ...

Exact Sciences Corporation (NASDAQ:EXAS) Q3 2020 Earnings Conference Call October 27, 2020 8:00 PM ET Company Participants Megan Jones - Associate Manager of Investor Relations Kevin Conroy - Chairman, President and Chief Executive Officer David Daly - Chief Executive Officer of Thrive Earlier Detection Corp. Jeffrey Elliott - Chief Financial Officer Conference Call Participants Brian Weinstein - William Blair & Company LLC Doug Schenkel - Cowen and Company, LLC Derik De Bruin - Bank of America Merrill Lync ...